Jaguar Health Inc.Find Ratings Reports
JAGUAR HEALTH INC's gross profit margin for the second quarter of its fiscal year 2019 has decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. JAGUAR HEALTH INC has very weak liquidity. Currently, the Quick Ratio is 0.18 which clearly shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 68.04% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY19||Q2 FY18|
|Net Sales ($mil)||1.71||0.88|
|Net Income ($mil)||-16.72||-7.66|
|Balance Sheet||Q2 FY19||Q2 FY18|
|Cash & Equiv. ($mil)||1.61||2.41|
|Total Assets ($mil)||36.07||46.16|
|Total Debt ($mil)||11.87||15.42|
|Profitability||Q2 FY19||Q2 FY18|
|Gross Profit Margin||26.1||31.22|
|Return on Assets||-121.48||-62.4|
|Return on Equity||-582.13||-129.45|
|Debt||Q2 FY19||Q2 FY18|
|Share Data||Q2 FY19||Q2 FY18|
|Shares outstanding (mil)||42.1||0.7|
|Div / share||0.0||0.0|
|Book value / share||0.17||32.86|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1110214.0||2822096.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Conducting a second comparison, its price-to-book ratio of 4.29 indicates a premium versus the S&P 500 average of 3.24 and a significant discount versus the subsector average of 9.60. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, JAGUAR HEALTH INC proves to trade at a discount to investment alternatives.
|JAGX NM||Peers 26.95||JAGX NM||Peers 17.53|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
JAGX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
JAGX's P/CF is negative making the measure meaningless.
|JAGX NM||Peers 14.88||JAGX NA||Peers 0.39|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
JAGX's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|JAGX 4.29||Peers 9.60||JAGX 61.06||Peers 516.14|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
JAGX is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, JAGX is expected to significantly trail its peers on the basis of its earnings growth rate.
|JAGX 5.25||Peers 6.55||JAGX 39.06||Peers 8.38|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
JAGX is trading at a discount to its subsector on this measurement.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
JAGX has a sales growth rate that significantly exceeds its peers.